BioRestorative Therapies (BRTX) Company Report

BioRestorative Therapies reported Q3 2025 revenues of $11,800, a significant decrease from $233,600 in Q3 2024, primarily due to the timing of biocosmeceutical orders. The company ended the quarter with $4.5 million in cash, cash equivalents, and marketable securities and no outstanding debt, supplemented by $1.1 million from a recent financing completed after quarter-end.
Enrollment in the BRTX-100 Phase II clinical trial for chronic lumbar disc disease is approaching completion, with over three-quarters of the target 99 patients enrolled. The company anticipates a Type B meeting with the FDA in December to discuss a potential accelerated BLA approval pathway, aiming to move directly to a pivotal Phase III study.
The company is advancing its ThermoSTEM metabolic program, continuing substantive discussions with an undisclosed commercial stage regenerative medicine company for a potential license agreement. This program recently secured a Japanese patent allowance for its allogeneic off-the-shelf brown adipose-derived stem cell technology.
BioRestorative is strategically expanding its biocosmeceuticals business, a $63 billion market opportunity, by rebuilding its commercial infrastructure and hiring Crystal Romano as Global Head of Commercial Operations to drive scalable revenue growth through diversified distribution channels.

Nov 12, 2025, 9:30 PM

BioRestorative Therapies Reports Q3 2025 Financial Results and Business Updates

BRTX

Earnings

New Projects/Investments

BioRestorative Therapies reported a significant decline in revenue for Q3 2025 to approximately $11,800, down from $233,600 in Q3 2024, primarily due to the timing of BioCosmeceutical orders. This resulted in a widened net loss of $3.0 million, or $0.33 per share, in Q3 2025, compared to a net loss of $1.0 million, or $0.13 per share, in the prior year's quarter.
The company ended Q3 2025 with $4.5 million in cash, cash equivalents, and investments and no outstanding debt. Subsequent to the quarter end in October, BioRestorative completed a registered direct offering, generating approximately $1.085 million in gross proceeds.
Key business updates include anticipating an FDA Type B meeting to discuss a potential accelerated Biologics License Application (BLA) pathway for its BRTX-100 program, receiving a Japanese patent for its ThermoStem® platform, and appointing Crystal Romano as Head of Global Commercial Operations.

Nov 12, 2025, 9:05 PM

BioRestorative Therapies Secures Japanese Patent for ThermoStem® Platform

BRTX

New Projects/Investments

BioRestorative Therapies (BRTX) has received a Notice of Allowance for its Japanese patent for the ThermoStem® platform, which provides broad protection for its allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) technology.
This patent covers the therapeutic cells themselves, as well as multiple methods of encapsulation and delivery, for technology designed to treat obesity and metabolic disorders.
The ThermoStem® platform is being developed as a potential cell-based alternative to GLP-1 drugs, aiming to offer longer-lasting efficacy with improved safety and dosing advantages, and to mitigate issues like muscle mass loss and cardiovascular risks associated with GLP-1 therapies.
BioRestorative is currently engaged in discussions with potential strategic partners regarding its metabolic intellectual property, positioning the company for commercial opportunities in the global obesity market, which is projected to exceed $100 billion annually by the end of the decade.

Oct 27, 2025, 11:30 AM

BioRestorative Therapies Announces Registered Direct Offering

BRTX

New Projects/Investments

BioRestorative Therapies, Inc. announced a $1.085 million registered direct offering of common stock and a concurrent private placement of unregistered warrants.
The offering includes the sale of 678,125 shares of common stock at $1.60 per share, priced above the market close of $1.50 on October 3, 2025.
Concurrently, the company will issue unregistered warrants to purchase up to 508,594 shares of common stock, with an exercise price of $2.75 per share.
The net proceeds from the offering are intended to fund clinical trials for BRTX-100, pre-clinical research and development for its ThermoStem® Program, development of its biocosmeceuticals platform, and general corporate purposes.
The closing of the offering is expected on or about October 8, 2025.